Microbot Medical Inc. (NASDAQ:MBOT) Expected to Post Q1 2024 Earnings of ($0.17) Per Share

Microbot Medical Inc. (NASDAQ:MBOT) – Equities researchers at HC Wainwright lifted their Q1 2024 earnings per share estimates for shares of Microbot Medical in a report released on Tuesday, April 16th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.13) EPS and FY2024 earnings at ($0.61) EPS.

Microbot Medical Price Performance

MBOT opened at $0.89 on Thursday. The stock has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.29. The firm has a market cap of $12.82 million, a PE ratio of -0.82 and a beta of 1.64. Microbot Medical has a 1 year low of $0.86 and a 1 year high of $4.37.

Hedge Funds Weigh In On Microbot Medical

Large investors have recently modified their holdings of the stock. Wells Fargo & Company MN raised its position in Microbot Medical by 6,713.4% in the 2nd quarter. Wells Fargo & Company MN now owns 12,741 shares of the biotechnology company’s stock worth $35,000 after buying an additional 12,554 shares during the last quarter. Hilltop Holdings Inc. purchased a new position in Microbot Medical in the 2nd quarter worth about $52,000. Virtu Financial LLC raised its position in Microbot Medical by 75.9% in the 4th quarter. Virtu Financial LLC now owns 42,046 shares of the biotechnology company’s stock worth $69,000 after buying an additional 18,138 shares during the last quarter. Cetera Advisor Networks LLC purchased a new position in Microbot Medical in the 1st quarter worth about $78,000. Finally, Renaissance Technologies LLC increased its position in shares of Microbot Medical by 52.5% during the 1st quarter. Renaissance Technologies LLC now owns 15,695 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 5,400 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.